. 2022 Jul 28;23(1):90. doi: 10.1186/s10194-022-01458-0

Table 2.

Primary and secondary endpoints

Endpoint	Time frame	LS Mean Change (SE)		LS Mean Change Difference / Odds Ratio (95% CI)	p-value
Endpoint	Time frame	Galcanezumab 120 mg	Placebo	LS Mean Change Difference / Odds Ratio (95% CI)	p-value
Monthly MHDs	Month 1–3	-3.81 (0.23)	-1.99 (0.23)	-1.82 (-2.32, -1.32)^a	< 0.0001
≥ 50% response rate	Month 1–3	54.9 (2.4)^b	32.9 (2.3)^b	2.48 (1.87, 3.29)^c	< 0.0001
MSQ-RFR	Month 1–3	21.01 (0.85)	13.94 (0.88)	7.07 (5.20, 8.95)^a	< 0.0001
≥ 75% response rate	Month 1–3	29.2 (2.1)^b	12.7 (1.6)^b	2.82 (2.01, 3.97)^c	< 0.0001
100% response rate	Month 1–3	11.9 (1.4)^b	3.9 (0.9)^b	3.31 (1.99, 5.50)^c	< 0.0001
Monthly MHDs treated with acute medication	Month 1–3	-2.49 (0.22)	-0.71 (0.22)	-1.78 (-2.25, -1.31)^a	< 0.0001
MSQ-Total Score	Month 1–3	19.73 (0.81)	13.56 (0.84)	6.17 (4.39, 7.95)^a	< 0.0001
MSQ-RFP	Month 1–3	18.79 (0.87)	12.76 (0.90)	6.03 (4.10, 7.95)^a	< 0.0001
MSQ-EF	Month 1–3	17.88 (0.98)	13.72 (1.02)	4.16 (2.00, 6.32)^a	0.0002
PGI-S	Month 3	-0.83 (0.09)	-0.61 (0.10)	-0.22 (-0.43, -0.02)^a	0.0284
MIDAS Total Score	Month 3	-22.61 (2.96)	-10.18 (3.06)	-12.43 (-18.81, -6.05)^a	0.0001

^aLS mean change difference

^bModel estimated rate

^cOdds ratio

CI Confidence interval, LS Least squares, MHD Migraine headache day, MIDAS Migraine Disability Assessment, MSQ-EF Migraine Specific Quality of Life Questionnaire Emotional Function, MSQ-RFP Migraine Specific Quality of Life Questionnaire Role Function-Preventive, MSQ-RFR Migraine Specific Quality of Life Questionnaire Role Function-Restrictive, PGI-S Patient Global Impression of Severity, SE Standard error